Pan Tumor Rollover Study
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.
Cancer
DRUG: Nivolumab|DRUG: Ipilimumab|DRUG: Cabozantinib|DRUG: Trametinib|DRUG: Relatlimab|DRUG: Nivolumab + Relatlimab|DRUG: Capecitabine|DRUG: Bevacizumab|DRUG: Temozolomide|DRUG: Rucaparib|DRUG: Daratumumab|DRUG: Regorafinib|DRUG: Leucovorin|DRUG: Fluorouracil|DRUG: Oxaliplatin|DRUG: Enzalutamide|DRUG: Sunitinib|DRUG: Pemetrexed|DRUG: Pembrolizumab
Incidence of Adverse Events (AEs), From Day 1 up to 135 Days after discontinuation of treatment|Incidence of drug related AEs, From Day 1 up to 135 Days after discontinuation of treatment|Incidence of AEs leading to Discontinuation, From Day 1 up to 135 Days after discontinuation of treatment|Incidence of Serious Adverse Events (SAEs), From signature of Informed Consent up to 135 Days after discontinuation of treatment|Incidence of Select AEs, From Day 1 up to 135 Days after discontinuation of treatment|Incidence of Immune-Mediated AEs, From Day 1 up to 135 Days after discontinuation of treatment|Incidence of Death, From signature of Informed Consent up to 135 Days after discontinuation of treatment
Main Objective of this study is to examine long-term safety of nivolumab monotherapy including combinations and other cancer therapies in various tumor types.